171 related articles for article (PubMed ID: 3917526)
1. Studies on the mechanism of action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Cohen G; Mytilineou C
Life Sci; 1985 Jan; 36(3):237-42. PubMed ID: 3917526
[TBL] [Abstract][Full Text] [Related]
2. Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice.
Fuller RW; Hemrick-Luecke SK; Kindt MV; Heikkila RE
Life Sci; 1988; 42(3):263-71. PubMed ID: 3121972
[TBL] [Abstract][Full Text] [Related]
3. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
4. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.
Chiba K; Trevor A; Castagnoli N
Biochem Biophys Res Commun; 1984 Apr; 120(2):574-8. PubMed ID: 6428396
[TBL] [Abstract][Full Text] [Related]
6. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P; Marsden CD
J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
[TBL] [Abstract][Full Text] [Related]
7. Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Fuller RW; Hemrick-Luecke SK; Perry KW
J Pharmacol Exp Ther; 1988 Nov; 247(2):531-5. PubMed ID: 3141609
[TBL] [Abstract][Full Text] [Related]
8. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correspondence of its binding sites to monoamine oxidase in rat brain, and inhibition of dopamine oxidative deamination in vivo and in vitro.
Bocchetta A; Piccardi MP; Del Zompo M; Pintus S; Corsini GU
J Neurochem; 1985 Sep; 45(3):673-6. PubMed ID: 3928808
[TBL] [Abstract][Full Text] [Related]
9. Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity?
Irwin I; Langston JW
Life Sci; 1985 Jan; 36(3):207-12. PubMed ID: 3871240
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs, 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine and 1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine, on monoamine oxidase in vitro and on dopamine in mouse brain.
Fuller RW; Robertson DW; Hemrick-Luecke SK
J Pharmacol Exp Ther; 1987 Feb; 240(2):415-20. PubMed ID: 3100775
[TBL] [Abstract][Full Text] [Related]
11. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.
Heikkila RE; Duvoisin RC; Finberg JP; Youdim MB
Eur J Pharmacol; 1985 Oct; 116(3):313-7. PubMed ID: 3935467
[TBL] [Abstract][Full Text] [Related]
12. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine destroys dopamine neurons in explants of rat embryo mesencephalon.
Mytilineou C; Cohen G
Science; 1984 Aug; 225(4661):529-31. PubMed ID: 6610939
[TBL] [Abstract][Full Text] [Related]
13. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine- and 1-methyl-4-(2'-ethylphenyl)-1,2,3,6-tetrahydropyridine-induced toxicity in PC12 cells: role of monoamine oxidase A.
Basma AN; Heikkila RE; Nicklas WJ; Giovanni A; Geller HM
J Neurochem; 1990 Sep; 55(3):870-7. PubMed ID: 2384758
[TBL] [Abstract][Full Text] [Related]
14. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.
Heikkila RE; Manzino L; Cabbat FS; Duvoisin RC
Nature; 1984 Oct 4-10; 311(5985):467-9. PubMed ID: 6332989
[TBL] [Abstract][Full Text] [Related]
15. Involvement of monoamine oxidase enzymes in the action of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, a selective neurotoxin, in the squirrel monkey: binding and biochemical studies.
Del Zompo M; Piccardi MP; Bernardi F; Bonuccelli U; Corsini GU
Brain Res; 1986 Jul; 378(2):320-4. PubMed ID: 3089539
[TBL] [Abstract][Full Text] [Related]
16. Development of fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs with potent nigrostriatal toxicity for potential use in positron emission tomography studies.
Harik SI; Riachi NJ; Hritz MA; Berridge MS; Sayre LM
J Pharmacol Exp Ther; 1993 Aug; 266(2):790-5. PubMed ID: 8355208
[TBL] [Abstract][Full Text] [Related]
17. Pargyline prevents MPTP-induced parkinsonism in primates.
Langston JW; Irwin I; Langston EB; Forno LS
Science; 1984 Sep; 225(4669):1480-2. PubMed ID: 6332378
[TBL] [Abstract][Full Text] [Related]
18. Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP.
Salach JI; Singer TP; Castagnoli N; Trevor A
Biochem Biophys Res Commun; 1984 Dec; 125(2):831-5. PubMed ID: 6335034
[TBL] [Abstract][Full Text] [Related]
19. Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity.
Kalaria RN; Mitchell MJ; Harik SI
Proc Natl Acad Sci U S A; 1987 May; 84(10):3521-5. PubMed ID: 3495000
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the mouse: relationships between monoamine oxidase, MPTP metabolism and neurotoxicity.
Heikkila RE; Hess A; Duvoisin RC
Life Sci; 1985 Jan; 36(3):231-6. PubMed ID: 3917525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
